secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001731122-26-000502
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lunai Bioworks enters $20M strategic acquisition; exchanges $828K debt for equity
--------------------------------------------------------------------------------

- Debt exchange: $828,770.14 principal and interest canceled for 3,909,293 shares at $0.21/share and warrants exercisable at $0.21 through 2036.
- Enters $20M strategic transaction for BBB delivery platform and CNS Alzheimer's drug assets from Clemann Group.
- Transaction structured as Series B Convertible Preferred at fixed $1.50 conversion price; no variable pricing or reset provisions.
- Platform enables compounds to cross BBB, remain inactive systemically, and activate in the brain; targets acetylcholinesterase pathways.
- CEO David Weinstein says transaction is a 'step-change' for CNS delivery capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/e7507_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-000502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer